45703
Erythromycin standard solution
1 mg/mL in H2O
別名:
Erythromycin from Streptomyces erythreus
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C37H67NO13
CAS番号:
分子量:
733.93
UNSPSC Code:
51282304
NACRES:
NA.85
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
8183758
製品名
Erythromycin standard solution, 1 mg/mL in H2O
InChI
1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
SMILES string
CC[C@H]1OC(=O)[C@H](C)C(O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)C(C)C(OC3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)C(O)[C@]1(C)O
InChI key
ULGZDMOVFRHVEP-RWJQBGPGSA-N
biological source
Streptomyces erythreus (strains)
agency
EPA 1694
form
liquid
concentration
1 mg/mL in H2O
color
colorless
antibiotic activity spectrum
Gram-positive bacteria
application(s)
environmental
mode of action
protein synthesis | interferes
storage temp.
2-8°C
Application
Erythromycin is an antibiotic produced by growth of certain strains of Streptomyces erythreus. This product is composed largely of erythromycin A with small amounts of erythromycins B and C and is recommended for concentration at 100 mg/L. Concentrations between 50 and 200 mg/L have also proven effective in controlling bacterial growth. Erythromycin has been used as a motilin receptor agonist, to block respiratory glycoconjugate secretion in human airways in vitro, and for selecting plasmid-cured and recombinant lactococcus lactis MG1363 strains. .
Biochem/physiol Actions
Mode of Action: Erythromycin acts by inhibiting elongation at the transpeptidation step, specifically aminoacyl translocation from the A-site to P-site by binding to the 50s subunit of the bacterial 70s rRNA complex.
Antimicrobial Spectrum: This product acts against both gram-negative and gram-positive bacteria.
Antimicrobial Spectrum: This product acts against both gram-negative and gram-positive bacteria.
Disclaimer
This Erythromycin solution is concentrated at 1 mg/mL in H2O and is stable in solution at 37°C for 3 days. Stock solutions should be stored at 2-8°C.
General description
Chemical structure: macrolide
Other Notes
Keep container tightly closed in a dry and well-ventilated place. Store under inert gas.
Packaging
10 ml
保管分類
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves
J I Alós et al.
The Journal of antimicrobial chemotherapy, 51(2), 333-337 (2003-02-04)
In 1998 we conducted a multicentre study in Spain on the susceptibility of Streptococcus pyogenes isolates to different 14-, 15- and 16-membered macrolides and clindamycin, in which the number of strains examined was proportional to the number of inhabitants in
Agot Aakra et al.
Antimicrobial agents and chemotherapy, 49(6), 2246-2259 (2005-05-27)
A transcriptional profile of Enterococcus faecalis V583 (V583) treated with erythromycin is presented. This is the first study describing a complete transcriptional profile of Enterococcus. E. faecalis is a common and nonvirulent bacterium in many natural environments, but also an
Pier Carlo Braga et al.
The Journal of antimicrobial chemotherapy, 50(4), 457-460 (2002-10-03)
The aim of this study was to use atomic force microscopy (AFM), an innovative type of microscopy, to investigate the different behaviours of erythromycin A (a 14-membered ring) and rokitamycin (a 16-membered ring) in disrupting the morphology of Streptococcus pyogenes
Christoph Czarnetzki et al.
JAMA surgery, 150(8), 730-737 (2015-06-18)
Patients undergoing emergency procedures under general anesthesia have impaired gastric emptying and are at high risk for aspiration of gastric contents. Erythromycin has strong gastric prokinetic properties. To evaluate the efficacy of erythromycin lactobionate in gastric emptying in patients undergoing
David J Serisier et al.
JAMA, 309(12), 1260-1267 (2013-03-28)
Macrolide antibiotics such as erythromycin may improve clinical outcomes in non-cystic fibrosis (CF) bronchiectasis, although associated risks of macrolide resistance are poorly defined. To evaluate the clinical efficacy and antimicrobial resistance cost of low-dose erythromycin given for 12 months to
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）